PolyPid stock received an Outperform rating from Oppenheimer on October 27, 2026, as the firm initiated coverage of the clinical-stage biopharmaceutical company with a $10.00 price target.

Key Takeaways

  • Oppenheimer’s $10.00 target is an analyst estimate, not a guaranteed share price.
  • PolyPid’s lead product candidate, D-PLEX100, is intended to prevent surgical site infections.

PolyPid stock rating and price target

The initiation covers PolyPid Ltd., which trades under the ticker PYPD. The $10.00 target was above a quoted share price of $5.29, although the time of that price observation was not specified.

The company’s market capitalization was approximately $107.45 million. PolyPid was described as unprofitable and cash-flow negative; no reporting period was specified for those measures.

Drug delivery technology and lead candidate

PolyPid is an Israeli clinical-stage biopharmaceutical company developing drug delivery technologies. Its PLEX technology encapsulates drugs for localized, controlled release.

The technology is used in the company’s lead product candidate, D-PLEX100, which is intended to prevent surgical site infections. The candidate remains in development.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.